Scilex Holding Company Enters into Master Distributor Agreement Among CH Trading Group and Devart Middle East for the Distribution of ZTlido® in Morocco, Tunisia, Libya, Jordan, Iraq, and South Africa

Core Insights - Scilex Holding Company has announced a Master Distributor Agreement with Devart Middle East and CH Trading Group to expand the distribution of ZTlido® into Morocco, Tunisia, Libya, Jordan, Iraq, and South Africa [1][2][3] Company Overview - Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for acute and chronic pain [7] - The company's commercial products include ZTlido®, ELYXYB®, and Gloperba®, targeting high unmet needs in pain management [7][8] Product Details - ZTlido® is a lidocaine topical system approved for neuropathic pain relief associated with post-herpetic neuralgia, designed for improved adhesion and continuous pain relief over a 12-hour period [4] - Over one million patients have been treated with ZTlido® in the U.S. since its launch, making it the number one prescribed non-opioid branded pain medication by pain specialists in 2023 [5] Distribution Strategy - The Master Distributor Agreement allows Devart Middle East to promote, market, sell, and distribute ZTlido® and potentially other Scilex products through a network of business associates in the designated territories [3][2] - This agreement builds on an existing Product Distribution Agreement with CH Trading Group, which is expanding ZTlido® commercialization in the Middle East and North/South Africa [2]